CtDNA-guided rechallenge with anti-EGFR therapy in RASwt metastatic colorectal cancer: Evidence from clinical practice.

Raffaella D'OnofrioFrancesco CaputoFrancesco PrampoliniAndrea SpallanzaniFabio GelsominoStefania BettelliSamantha ManfrediniLuca Reggiani BonettiPietro CarotenutoAlessandro BocconiMassimo DominiciGabriele LuppiMassimiliano Salati

Published in: Tumori (2022)

Blood-based RASwt status may enrich metastatic colorectal cancer more likely to benefit from anti-EGFR-based rechallenge. RAS genotyping in ctDNA represents a feasible, fast, and cost-effective tool to be implemented in the clinic for advancing precision medicine.

Keyphrases

metastatic colorectal cancer
small cell lung cancer
epidermal growth factor receptor
clinical practice
tyrosine kinase
circulating tumor
primary care
high throughput
stem cells
gene expression
cell therapy